{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:32:50Z","timestamp":1791340370128,"version":"4.3.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1136\/ard.2005.048371","type":"journal-article","created":{"date-parts":[[2006,1,5]],"date-time":"2006-01-05T20:25:21Z","timestamp":1136492721000},"page":"1006-1012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":263,"title":["Safety of extended treatment with anakinra in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"65","author":[{"given":"R M","family":"Fleischmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Tesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Schechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G-R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Modafferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Appleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2005.048371_bib1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/art.1780400517","article-title":"Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee","volume":"40","author":"Bakker","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib2","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.4049\/jimmunol.156.9.3558","article-title":"Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy","volume":"156","author":"Otani","year":"1996","journal-title":"J Immunol"},{"key":"10.1136\/ard.2005.048371_bib3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.1780390513","article-title":"Anticytokine treatment of established type II collagen-induced arthritis in DBA\/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha\/beta, and IL-1Ra","volume":"39","author":"Joosten","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib4","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib5","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/art.10578","article-title":"Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Nuki","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P","article-title":"A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores","volume":"43","author":"Jiang","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib8","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib9","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/art.20277","article-title":"The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions","volume":"50","author":"Schiff","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib10","first-page":"649","article-title":"Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis","volume":"31","author":"Tesser","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.048371_bib11","first-page":"948","article-title":"Prevalence of self-reported arthritis or chronic joint symptoms among adults \u2013 United States, 2001","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1136\/ard.2005.048371_bib12","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.048371_bib13","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib14","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib15","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.048371_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.048371_bib17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2005.048371_bib18","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.rdc.2004.02.003","article-title":"Safety overview of new disease-modifying antirheumatic drugs","volume":"30","author":"Cush","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard.2005.048371_bib20","first-page":"1942","article-title":"Infections in rheumatoid arthritis \u2013 a new phenomenon?","volume":"28","author":"Doran","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.048371_bib21","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0889-857X(05)70327-6","article-title":"Infectious complications of immunosuppressive therapy in patients with rheumatic diseases","volume":"23","author":"Segal","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard.2005.048371_bib23","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib24","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.048371_bib25","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.048371_bib26","first-page":"1238","article-title":"Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis","volume":"28","author":"Moreland","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.048371_bib27","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","article-title":"Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events","volume":"96","author":"Saag","year":"1994","journal-title":"Am J Med"},{"key":"10.1136\/ard.2005.048371_bib29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.1780310513","article-title":"Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism","volume":"31","author":"van Albada-Kuipers","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib30","unstructured":"Kineret (anakinra) FDA briefing information, 16 August 2001. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3779b1_01_Amgen.pdf (accessed 18 November 2005)."},{"key":"10.1136\/ard.2005.048371_bib31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.048371_bib32","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib33","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.2005.048371_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048371_bib35","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2003.009563","article-title":"Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study","volume":"62","author":"van de Putte","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.048371_bib36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","article-title":"Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed","volume":"63","author":"van de Putte","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.048371_bib37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","article-title":"Incidence of cancer among patients with rheumatoid arthritis","volume":"85","author":"Gridley","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ard.2005.048371_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/ard.43.2.128","article-title":"Cancer morbidity in rheumatoid arthritis","volume":"43","author":"Prior","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.048371_bib39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/ard.43.2.132","article-title":"Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases","volume":"43","author":"Symmons","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.048371_bib40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0002-9343(85)90241-4","article-title":"Neoplasms of the immune system in rheumatoid arthritis","volume":"78","author":"Symmons","year":"1985","journal-title":"Am J Med"},{"key":"10.1136\/ard.2005.048371_bib41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"10.1136\/ard.2005.048371_bib42","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","article-title":"Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis","volume":"31","author":"Isomaki","year":"1978","journal-title":"J Chronic Dis"},{"key":"10.1136\/ard.2005.048371_bib43","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0895-4356(93)90049-7","article-title":"Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the Province of Saskatchewan, Canada","volume":"46","author":"Tennis","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1136\/ard.2005.048371_bib44","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724200819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724200819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2005.048371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T09:28:21Z","timestamp":1736069301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724200819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0003496724200819"],"URL":"https:\/\/doi.org\/10.1136\/ard.2005.048371","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2005.048371","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Copyright 2006 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}